A Phase I, first-in-human, randomized, double-blind, placebo-controlled, single ascending dose clinical trial to evaluate the safety, tolerability, PK profile, and immunogenicity of BIO89-100 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs BIO 89 100 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors 89bio
- 11 Nov 2019 Results published in the 89bio Media Release.
- 11 Nov 2019 According to an 89bio Media Release, results from this study will be presented today at The Liver Meeting 2019.
- 22 May 2019 Status changed from recruiting to completed, according to the 89bio Media Release.